Filing Flows › Amneal Pharmaceuticals (AMRX) › Capital expenditures
Amneal Pharmaceuticals (AMRX) capital expenditures by quarter
Amneal Pharmaceuticals' capital expenditures were $31.8M in Q3 2026 (third quarter 2026), +46% from Q4 2025. Over the last 5 quarters it ranged from $12.3M (Q3 2025) to $31.8M (Q3 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $31.8M | +46% | +158% |
| Q4 2025 | $21.8M | +77% | — |
| Q3 2025 | $12.3M | -46% | — |
| Q2 2025 | $22.8M | +73% | — |
| Q1 2025 | $13.2M | — | — |
Q3 2026 at a glance
Amneal Pharmaceuticals, Q3 2026: revenue $863M (+10% year over year), operating margin 11.1%, net earnings $12.3M, operating cash flow $98.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Amneal Pharmaceuticals' capital expenditures?
Amneal Pharmaceuticals' capital expenditures were $31.8M in Q3 2026 (third quarter 2026), +46% from Q4 2025.
How has Amneal Pharmaceuticals' capital expenditures changed?
Over the last 5 quarters it ranged from $12.3M (Q3 2025) to $31.8M (Q3 2026).
Q3 2026 results → · How Amneal Pharmaceuticals makes money →